Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such investors are ...

Organogenesis (ORGO) and MiMedx (MDXG) traded lower on Friday after the Centers for Medicare & Medicaid Services (CMS) ...

Medicare's decision to slash the cost of wound-care products is shoving the regenerative medicine company Organogenesis toward a major restructuring, with the CEO conceding to staffers that "heart ...

Organogenesis shares have dropped ~42% since my last 'Hold' rating, reflecting ongoing challenges in its core business. Q1 2025 earnings disappointed, with the dominant Advanced Wound Care segment ...

CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of ...

Despite Q2/2025 revenue and EPS misses, Organogenesis shares have shown resilience, rarely dipping below $3.00 since June. The company cut 2025 guidance for Advanced Wound Care products, citing ...

To get a sense of who is truly in control of Organogenesis Holdings Inc. (NASDAQ:ORGO), it is important to understand the ownership structure of the business. We can see that individual insiders own ...

To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results. The wound care ...

Integra LifeSciences said on Tuesday that it was doing a voluntary recall of products, which could be worth as much as $60 million if the recall lasts all of 2023. Integra said it was doing a global ...

Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu. The regenerative tissue company said Monday it plans ...

One of the first things visitors to the Organogenesis production areas see are two numbers – 10,000 and 100. The Canton biotech firm’s skin-regeneration business starts with those numbers, which show ...

Organogenesis Inc., a Canton biotech that sells wound care and skin graft products, is going public again, 16 years after it went private amid financial problems. The biotech, founded in 1985 as a ...